This author has yet to write their bio.Meanwhile lets just say that we are proud IDEAL contributed a whooping 60 entries.
The Japanese Pharmaceutical and Medical Devices Agency (PMDA) mentiones IDeAl explicitly in their latest newsletter. Peter Bauer, Martin Posch and Franz König explained the IDeAL project for PDMDA staff members and gave a special training on adaptive designs with the title “Trends in adaptive design and statistical approaches to small population group trials in EU”, […]
Ralf-Dieter Hilgers has been invited to serve as an IRDiRC Task Force Member to advance progress in the field of Small Population Clinical trials. With this Task Force, the International Rare Disease Consortium aims at delivering 200 new therapies for rare diseaes and at the means to diagnose most rare diseases by 2020. IDeAl has […]
In the week 6-10 July 2015, there will be a workshop on Design and Analysis of Experiments in Healthcare at the Isaac Newton Institute, Cambridge, UK. This workshop is a follow-on to the 2011 six-month research programme on Design and Analysis of Experiments at INI, and is partly funded by IDEAL. In due course, there […]
The Rare Disease Day takes place every year on the last day of February. According to the initiatives website, the main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives. It has notably contributed to the advancement of national plans […]
The International Biometric Society IBS mention the joint seminar with IdeAl in its current Biometric Bulletin. The seminar was organized jointly by the IDeAl project and the WBS. The half day workshop on clinical trial methodology featured talks from Stephen Senn, Holger Dette, Bill Rosenberger, Ralf-Dieter Hilgers Gerald Hlavin and Sergey Krasnozhon.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKBy continuing to use the site, you agree to the use of cookies. more information